One of the hallmarks of cancer is deregulation of signal transduction – cancer cells are experts in rewiring proteomic, transcriptional, and epigenetic networks to drive cell growth and survival. While these pathways identify targetable vulnerabilities in cancer, there remains a shortage of targeted agents that disrupt critical signaling nodes and/or overcome drug resistance. The Nabet lab is dedicated to targeting oncogenic signaling networks through control of protein homeostasis to advance new therapeutic strategies in cancer.
Ferguson FM*, Nabet B*, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, Koren J, Dieguez-Martinez N, Espinosa S, Zeng Z, Corona CR, Vasta JD, Ohi R, Sim T, Kim ND, Harshbarger W, Lizcano JM, Robers MB, Muthaswamy S, Lin CY, Look AT, Haigis KM, Mancias JD, Wolpin BM, Aguirre AJ, Hahn WC, Westover KD, Gray NS. (2020).
Nabet B*,#, Ferguson FM*, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, Robichaud A, Conway AS, Buckley DL, Mancias JD, Bradner JE, Stegmaier K, Gray NS#. (2020).
Nabet B*, Roberts JM*, Buckley DL*, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong K-KK, Gray NS, Bradner JE. (2018).